衰老影响甲状腺癌发生发展的机制研究进展

doi:10.3969/j.issn.1004-616x.2025.04.012

Abstract

CLC Number:

R363.2+1

LIANG Xinen, XIAO Ting, GUO Huiqin. Research progress on the mechanism of aging affecting the occurrence and development of thyroid cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 304-307.

References

[1] MONTéGUT L, LóPEZ-OTíN C, KROEMER G. Aging and cancer[J]. Mol Cancer, 2024, 23(1): 106.
[2] VAN HERCK Y, FEYAERTS A, ALIBHAI S, et al. Is cancer biology different in older patients-[J]. Lancet Healthy Longev, 2021, 2(10): e663-e677.
[3] AMIN M B, GREENE F L, EDGE S B, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging[J]. CA Cancer J Clin, 2017, 67(2): 93-99.
[4] AUNAN J R, CHO W C, SØREIDE K. The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks[J]. Aging Dis, 2017, 8(5): 628-642.
[5] WAKIYAMA H, MASUDA T, MOTOMURA Y, et al. Cytolytic activity (CYT) score is a prognostic biomarker reflecting host immune status in hepatocellular carcinoma (HCC)[J]. Anticancer Res, 2018, 38(12): 6631-6638.
[6] 姚承志, 张敏, 曾雨可, 等. 中国甲状腺癌发病和死亡趋势分析与预测[J]. 中华流行病学杂志, 2023, 44(6): 917-923.
[7] TONIATO A, BERNARDI C, PIOTTO A, et al. Features of papillary thyroid carcinoma in patients older than 75 years[J]. Updates Surg, 2011, 63(2): 115-118.
[8] GESING A, LEWI-SKI A, KARBOWNIK-LEWI-SKA M. The thyroid gland and the process of aging；what is new-[J]. Thyroid Res, 2012, 5(1): 16.
[9] KIM T Y, KIM K W, JUNG T S, et al. Prognostic factors for Korean patients with anaplastic thyroid carcinoma[J]. Head Neck, 2007, 29(8): 765-772.
[10] MINNA E, BRICH S, TODOERTI K, et al. Cancer associated fibroblasts and senescent thyroid cells in the invasive front of thyroid carcinoma[J]. Cancers (Basel), 2020, 12(1): 112.
[11] KIM Y H, CHOI Y W, LEE J, et al. Senescent tumor cells lead the collective invasion in thyroid cancer[J]. Nat Commun, 2017, 8: 15208.
[12] VAN H D. The ageing thyroid: implications for longevity and patient care[J]. Nat Rev Endocrinol, 2024, 20(1): 5-15.
[13] SAJINA Z. Role of TSH in predicting malignant thyroid tumours[J]. J Surg Res Pract, 2025: 1-5.
[14] SAKORAFAS G H, PEROS G, FARLEY D R. Thyroid nodules: does the suspicion for malignancy really justify the increased thyroidectomy rates-[J]. Surg Oncol, 2006, 15(1): 43-55.
[15] KIM T H, LEE M Y, JIN S M, et al. The association between serum concentration of thyroid hormones and thyroid cancer: a cohort study[J]. Endocr Relat Cancer, 2022, 29(12): 635-644.
[16] 梁月辉, 肖芳. 衰老相关分泌表型对恶性肿瘤的双向调节作用[J]. 中华老年医学杂志, 2020(8): 971-975.
[17] RUHLAND M K, LOZA A J, CAPIETTO A H, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis[J]. Nat Commun, 2016, 7: 11762.
[18] HIRATA T, ARAI Y, YUASA S, et al. Associations of cardiovascular biomarkers and plasma albumin with exceptional survival to the highest ages[J]. Nat Commun, 2020, 11(1): 3820.
[19] DEMARIA M, O’LEARY M N, CHANG J H, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse[J]. Cancer Discov, 2017, 7(2): 165-176.
[20] HIERONYMUS H, MURALI R, TIN A, et al. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death[J]. eLife, 2018, 7: e37294.
[21] RUIZ E, KANDIL E, ALHASSAN S, et al. An integrative multi-omics analysis of the molecular links between aging and aggressiveness in thyroid cancers[J]. Aging Dis, 2023, 14(3): 992-1012.
[22] WREESMANN V B, SIECZKA E M, SOCCI N D, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker[J]. Cancer Res, 2004, 64(11): 3780-3789.
[23] CANCER Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma[J]. Cell, 2014, 159(3): 676-690.
[24] KJELLMAN P, LAGERCRANTZ S, H--G A, et al. Gain of 1q and loss of 9q21.3-Q32 are associated with a less favorable prognosis in papillary thyroid carcinoma[J]. Genes Chromosomes Cancer, 2001, 32(1): 43-49.
[25] GIRALDO N A, SANCHEZ-SALAS R, PESKE J D, et al. The clinical role of the TME in solid cancer[J]. Br J Cancer, 2019, 120(1): 45-53.
[26] YANG Z, WEI X Y, PAN Y T, et al. A new risk factor indicator for papillary thyroid cancer based on immune infiltration[J]. Cell Death Dis, 2021, 12(1): 51.
[27] FRENCH J D, BIBLE K, SPITZWEG C, et al. Leveraging the immune system to treat advanced thyroid cancers[J]. Lancet Diabetes Endocrinol, 2017, 5(6): 469-481.
[28] QING W, FANG W Y, YE L, et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma[J]. Thyroid, 2012, 22(9): 905-910.
[29] KIM S, CHO S W, MIN H S, et al. The expression of tumor-associated macrophages in papillary thyroid carcinoma[J]. Endocrinol Metab (Seoul), 2013, 28(3): 192-198.
[30] RYDER M, GHOSSEIN R A, RICARTE-FILHO J C M, et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer[J]. Endocr Relat Cancer, 2008, 15(4): 1069-1074.
[31] CAILLOU B, TALBOT M, WEYEMI U, et al. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma[J]. PLoS One, 2011, 6(7): e22567.
[32] MAZZONI M, MAURO G, ERRENI M, et al. Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism[J]. J Exp Clin Cancer Res, 2019, 38(1): 208.
[33] HSIAO S J, NIKIFOROV Y E. Molecular approaches to thyroid cancer diagnosis[J]. Endocr Relat Cancer, 2014, 21(5): T301-T313.
[34] WANG T T, SHI J Y, LI L C, et al. Single-cell transcriptome analysis reveals inter-tumor heterogeneity in bilateral papillary thyroid carcinoma[J]. Front Immunol, 2022, 13: 840811.
[35] ATTIA A S, HUSSEIN M, ISSA P P, et al. Association of BRAFV600E mutation with the aggressive behavior of papillary thyroid microcarcinoma: a meta-analysis of 33 studies[J]. Int J Mol Sci, 2022, 23(24): 15626.
[36] ELISEI R, UGOLINI C, VIOLA D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year Median follow-up study[J]. J Clin Endocrinol Metab, 2008, 93(10): 3943-3949.
[37] JIN L P, CHEN E D, DONG S Y, et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients[J]. Oncotarget, 2016, 7(14): 18346-18355.
[38] KIM S J, LEE K E, MYONG J P, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012, 36(2): 310-317.
[39] LANDA I, IBRAHIMPASIC T, BOUCAI L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers[J]. J Clin Invest, 2016, 126(3): 1052-1066.
[40] HAN Y, XU S J, CHENG K, et al. CENPF promotes papillary thyroid cancer progression by mediating cell proliferation and apoptosis[J]. Exp Ther Med, 2021, 21(4): 401.
[41] WANG S N, WU J, GUO C C, et al. Identification and validation of novel genes in anaplastic thyroid carcinoma via bioinformatics analysis[J]. Cancer Manag Res, 2020, 12: 9787-9799.
[42] LIU M, QIU Y L, JIN T, et al. Meta-analysis of microarray datasets identify several chromosome segregation-related cancer/testis genes potentially contributing to anaplastic thyroid carcinoma[J]. PeerJ, 2018, 6: e5822.

Research progress on the mechanism of aging affecting the occurrence and development of thyroid cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments